Catalyst

Slingshot members are tracking this event:

Theravance Biopharma (TBPH) due to initiate phase 1 trial of IND candidate TD-1473 for treatment of ulcerative colitis in late 2016 - 2017

Source Link:
http://seekingalpha.com/article/3669786-theravance-biopharmas-tbph-ceo-rick-winningham-q3-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TBPH
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 04, 2016
Occurred Source:
http://investor.theravance.com/releasedetail.cfm?ReleaseID=992002
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Trial, Td-1473, Ulcerative Colitis
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.